Navigation Links
HPS Files Comprehensive Patent Outside the Unites States for Mood-Enhancing Compound Naturally Found in Sea Coral
Date:1/15/2009

SAN JOSE, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") announced that it has filed a Comprehensive Patent Application with the International Bureau of the World Patent Office for the use of its innovative and previously undeveloped compound with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships, personal well-being and social attraction.

"We recently announced that we had filed an application with the U.S. Patent and Trademark Office for this compound, labeled as ER 303, and we have now followed-up with a patent application with the International Bureau that will cover major countries outside the United States," a spokesperson indicated. "This unique technology has worldwide applications, and, as such, we are also seeking to protect its value in Europe and other primary consumer markets outside the United States. Seeking this protection is critical in that we are seeking licensing opportunities with companies having a worldwide marketing and product presence." The Company reiterated that prior to its reproduction of this compound, it could only be found in coral reefs off the coasts of Newfoundland and in the waters off Brazil's Guiabinha Island.

The Company has previously been granted broad-based worldwide patents for its initial compound, Androstadienone, which has been licensed to leading marketers, including Johnson & Johnson, Avon and Schwarkopf and Henkel and its affiliates. An HPS spokesperson indicated that the Company believes that this additional filing on its new compound should be of interest to the major consumer products companies around the world.

This news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10- KSB for the year ended December 31, 2007, and Form 10-Q for the nine months ended September 30, 2008 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rodobo International, Inc. Files Fiscal Year 2008 SEC Form 10-K
2. Lilly Files Form 8-K/A Detailing Pro Forma Impact of ImClone Acquisition
3. Nolan Law Group Files Lawsuit on Behalf of the Parents of a 14-Month-Old Girl Killed in October 15th 2008 Medical Evacuation Helicopter Crash Near Aurora, Illinois
4. Scantek Medical Files for Chapter 11 Voluntary Bankruptcy and Receives Orders for the Sale of BreastCare(TM)
5. Californian Files Contact Lens Solution False Advertising Class Action Against Advanced Medical Optics, Announces the Schmidt Firm, LLP
6. HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral
7. AMERIGROUP Files Shelf Registration Statement
8. PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
9. Bally Total Fitness Files for Chapter 11 Bankruptcy Protection
10. Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution
11. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Miami native ... as a dentist. , “I could have never imagined back in 1991 that this ... said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant ...
(Date:4/26/2017)... Pa. (PRWEB) , ... April ... ... division, which provides an agile ecosystem and domain expertise for sponsors and ... configurable randomization and trial supply management (RTSM) software platform. Bioclinica AGILE ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... preferred physical therapy provider for Derby City CrossFit, effective immediately. , In addition ... quickly and effectively as possible, ProRehab’s sports physical therapists will work with athletes ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... Liberty attempts to compare student test score performance for the 2015-16 school year ... the state’s voucher programs. Though it highlights important patterns in student test score ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
Breaking Medicine Technology: